Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06977451 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Personalized Antisense Oligonucleotide for a Single Participant With CHCHD10 ALS

StatusActive, Not Recruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary and study completion dates: Jun 2026 to Jun 2027v3
  2. Primary and study completion dates: Jun 2025 to Jun 2026v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
n-Lorem Foundation
17 trials monitored
See all monitored trials
ALS
398 trials monitored
See 21 trials at risk
This research project entails delivery of a personalized antisense oligonucleotide (ASO) drug designed for a single participant with amyotrophic lateral sclerosis (ALS) due to a pathogenic variant in CHCHD10
Trial Details
NCT Number NCT06977451
Lead Sponsor n-Lorem Foundation
Collaborators: Columbia University
Conditions
(from sponsor)		 Amyotrophic Lateral Sclerosis
Related terms Amyotrophic Lateral Sclerosis
Enrollment 1 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov